NOTICE OF UPGRADE
Our websites will be unavailable between the hours of AEST 4AM September 17, 2022 and AEST 11PM on date September 18, 2022
SEARCH LISTED COMPANY
Any AUS or NZ company
SEARCH PRIVATE COMPANY
SEARCH FUNDS
Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:
|
|
17 May 2025
| Name: | MEDADVISOR LIMITED (MDR) | ||||||
| ISIN: | AU000000MDR6 | ||||||
| Date of Listing: | 26 May 2011 | ||||||
| Former Names: |
|
Stock Exchange Status: (updated daily)
This entity is currently listed and quoted on the Australian Securities Exchange.Legal Status: (updated monthly)
ACN: 145 327 617ABN: 17 145 327 617
Registration Date: 21 July 2010
Capital Gains Tax (CGT) Status: (updated at least quarterly)
To crystallise a capital gain or capital loss on your securities in this entity, you are able to sell your securities on-market in the normal manner. If you determine that the market in your securities is illiquid and you still wish to crystallise a capital gain or loss, kindly contact deListed at admin@delisted.com.au for suggestions as to how you might proceed.
Updates, corrections, disagreements please email to admin@delisted.com.au
Further information: deListed and InvestoGain are operated by Investogain Pty Limited which is licensed by ASIC as an Australian Financial Services Licensee (AFSL 334036). deListed acquires only securities that it deems to be of little or no value, in circumstances where the holder is unable to sell their securities on-market in the normal manner. This service has been provided online via the company’s website www.delisted.com.au since 2004.
Getting advice: Information provided in this section is of a general nature and applicable only to Australian tax residents who hold their investments on capital account (ie for long-term investment purposes). It has been prepared without taking into account your financial needs or tax situation. Before acting on the information, deListed suggests that you consider whether it is appropriate for your circumstances and recommends that you seek independent legal, financial, or taxation advice.
Disclaimer: The information provided above is to the best of our knowledge accurate as of today. But you should bear in mind that it is of a general nature and does not constitute financial or tax advice. Investogain Pty Limited accepts no liability for any loss arising from reliance on this information, including reliance on information that is no longer current.
| FROM | TO | |
| MEDADVISOR LIMITED | 30/11/2015 | |
| EXALT RESOURCES LIMITED | 30/11/2015 |
Computershare Melbourne
Yarra Falls, 452 Johnston Street, Abbotsford VIC 3067
Tel : +61 (0)3 9415 4000 or 1300 850 505 (within Australia)
Fax : +61 3 9473 2500
RegistryWebsite RegistryEmail
Expand this box to read and print
The suspension of trading in the securities of MedAdvisor Limitedwill be lifted immediatly following the release by MDR of an announcement regarding the outcome of a Court application under section 1322 of the Corporations Act 2001. | 02/05/2025 |
The company has received court orders to rectify an administrative oversight related to the late placement of a cleansing notice for fully paid ordinary shares. | 02/05/2025 |
The company releases its appendix 3G. | 01/05/2025 |
The company releases its 3Q FY25 Presentation. | 30/04/2025 |
The company releases its 4C and quarterly activity report. | 30/04/2025 |
The company will hold a 3Q FY25 investor webinar on 30 April 2025, featuring a presentation by CEO Rick Ratliff and CFO Ancila Desai. | 29/04/2025 |
The securities of MedAdvisor Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of MDR, pending the release of an announcement regarding a pending Court application under section 1322 of the Corporations Act 2001 deeming the cleansing notice lodged on the ASX Market Announcements Platform on 23 April 2025 to be effective from the date of issue of the shares the subject of the Cleansing Notice. | 29/04/2025 |
The suspension of trading in the securities of MedAdvisor Limited will be lifted immediately, following the release by MDR of an announcement regarding the outcome of the Placement and the institutional component of the Entitlement Offer. | 12/11/2020 |
MedAdvisor successfully completes placement and institutional entitlement offer with $35 million to acquire US-based Adheris Health. | 12/11/2020 |
The company requests that a further voluntary suspension of the company's securities from the commencement of trading on 10 November 2020 until the earliest of such time as the company makes an announcement in relation to the outcome of the institutional component of the offer; the opening of trading on 12 November 2020; and the company separately requests that the voluntary suspension be lifted. | 10/11/2020 |
The company requests a further voluntary suspension of its securities from the commencement of trading on 10 November 2020 until the earliest of: such time as the company makes an announcement to the market in relation to the outcome of the institutional component of the offer; the open of trading on 12 November 2020; and the company separately requests that the voluntary suspension be lifted. | 10/11/2020 |
The company releases a cleansing notice in respect of accelerated non-renounceable pro-rata entitlement offer. | 06/11/2020 |
The company releases an investor presentation update on the Adheris acquisition. | 06/11/2020 |
The company has adjusted the price for the capital raise as it forges ahead to acquire US-based Adheris Health. MedAdvisor has elected to price the deal at 38 cents which is expected to allow the company to attract a broader cohort of new strategic investors to the register. The maximum amount that MedAdvisor may raise under the placement is approximately AUD $23.5M. The maximum amount that MedAdvisor may raise under the entitlement offer is approximately AUD $37.7M. | 06/11/2020 |
The securities of MedAdvisor Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of MDR, pending the release of an announcement regarding an acquisition and a capital raising. | 06/11/2020 |
we understand that on or about this date the company consolidated its shares 1 for 7 | 28/11/2019 |
The securities of MedAdvisor Limited (formerly Exalt Resources Limited) (the "Company") will be reinstated to official quotation from the commencement of trading on Tuesday 1 December 2015, following the Company's compliance with Listing Rule 11.1.3 and Chapters 1 and 2 of the ASX Listing Rules. 387,406,652 fully paid ordinary shares Security Code: MDR | 30/11/2015 |
name changed from Exalt Resources Limited | 30/11/2015 |
The suspension of trading in the securities of MedAdvisor Limitedwill be lifted immediatly following the release by MDR of an announcement regarding the outcome of a Court application under section 1322 of the Corporations Act 2001. | 02/05/2025 |
The company has received court orders to rectify an administrative oversight related to the late placement of a cleansing notice for fully paid ordinary shares. | 02/05/2025 |
The company releases its appendix 3G. | 01/05/2025 |
The company releases its 3Q FY25 Presentation. | 30/04/2025 |
The company releases its 4C and quarterly activity report. | 30/04/2025 |
The company will hold a 3Q FY25 investor webinar on 30 April 2025, featuring a presentation by CEO Rick Ratliff and CFO Ancila Desai. | 29/04/2025 |
The securities of MedAdvisor Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of MDR, pending the release of an announcement regarding a pending Court application under section 1322 of the Corporations Act 2001 deeming the cleansing notice lodged on the ASX Market Announcements Platform on 23 April 2025 to be effective from the date of issue of the shares the subject of the Cleansing Notice. | 29/04/2025 |
The suspension of trading in the securities of MedAdvisor Limited will be lifted immediately, following the release by MDR of an announcement regarding the outcome of the Placement and the institutional component of the Entitlement Offer. | 12/11/2020 |
MedAdvisor successfully completes placement and institutional entitlement offer with $35 million to acquire US-based Adheris Health. | 12/11/2020 |
The company requests that a further voluntary suspension of the company's securities from the commencement of trading on 10 November 2020 until the earliest of such time as the company makes an announcement in relation to the outcome of the institutional component of the offer; the opening of trading on 12 November 2020; and the company separately requests that the voluntary suspension be lifted. | 10/11/2020 |
The company requests a further voluntary suspension of its securities from the commencement of trading on 10 November 2020 until the earliest of: such time as the company makes an announcement to the market in relation to the outcome of the institutional component of the offer; the open of trading on 12 November 2020; and the company separately requests that the voluntary suspension be lifted. | 10/11/2020 |
The company releases a cleansing notice in respect of accelerated non-renounceable pro-rata entitlement offer. | 06/11/2020 |
The company releases an investor presentation update on the Adheris acquisition. | 06/11/2020 |
The company has adjusted the price for the capital raise as it forges ahead to acquire US-based Adheris Health. MedAdvisor has elected to price the deal at 38 cents which is expected to allow the company to attract a broader cohort of new strategic investors to the register. The maximum amount that MedAdvisor may raise under the placement is approximately AUD $23.5M. The maximum amount that MedAdvisor may raise under the entitlement offer is approximately AUD $37.7M. | 06/11/2020 |
The securities of MedAdvisor Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of MDR, pending the release of an announcement regarding an acquisition and a capital raising. | 06/11/2020 |
we understand that on or about this date the company consolidated its shares 1 for 7 | 28/11/2019 |
The securities of MedAdvisor Limited (formerly Exalt Resources Limited) (the "Company") will be reinstated to official quotation from the commencement of trading on Tuesday 1 December 2015, following the Company's compliance with Listing Rule 11.1.3 and Chapters 1 and 2 of the ASX Listing Rules. 387,406,652 fully paid ordinary shares Security Code: MDR | 30/11/2015 |
name changed from Exalt Resources Limited | 30/11/2015 |
Your browser may reflect a date of printing in American format.
Purchases Sales
| DATE | DIRECTOR | NUMBER | PRICE | AMOUNT |
|---|---|---|---|---|
| 08/11/2023 | Jim Xenos | -6,846,955 | $0.180 | $1,232,452 |
| 17/11/2021 | Jim Xenos | -6,846,955 | $0.360 | $2,464,904 |
| 27/06/2017 | Peter Bennetto | 15,000 | $0.280 | $4,200 |
| 15/03/2017 | Jim Xenos | 300,000 | $0.032 | $9,630 |
| 15/03/2017 | Peter Bennetto | 200,000 | $0.032 | $6,400 |
| NAME | TITLE | DATE OF APPT |
|---|---|---|
| Rick Ratliff | Managing Director, CEO | 18/07/2022 |
| Ruba El-Afifi | COO | 10/08/2021 |
| Ancila Desai | CFO, Company Secretary | 17/10/2022 |
| Lucas Merrow | Non Exec Director | 10/08/2021 |
| Kevin Hutchinson | Non Exec Director | 23/11/2022 |
| Sandra Hook | Non Exec Director | 19/01/2016 |
| Kate Hill | Interim Chairman | 24/05/2023 |
| Jim Xenos | Director | |
| Gillian Nairn | Company Secretary | 11/12/2024 |
Date of first appointment, title may have changed.
| NAME | TITLE | DATE OF APPOINTMENT | DATE OF RESIGNATION |
|---|---|---|---|
| Linda Jenkinson | Non Exec Chairman | 28/02/2022 | 01/04/2025 |
| Anshu Raghuvanshi | Company Secretary | 11/12/2024 | |
| Anthony Tassone | Non Exec Director | 27/07/2022 | 15/10/2024 |
| Brett Magun | Non Exec Director | 24/05/2023 | 28/08/2024 |
| RaeAnn Grossman | Non Exec Director | 01/02/2022 | 21/04/2023 |
| Robert Read | Executive Director | 30/11/2022 | |
| Annabelle Grant | CFO | 15/07/2022 | 17/10/2022 |
| Josh Swinnerton | Executive Director | 12/11/2015 | 27/07/2022 |
| Simon Glover | CFO | 31/07/2019 | 15/07/2022 |
| Chris Ridd | Non Exec Chairman | 18/02/2020 | 28/02/2022 |
| Peter Bennetto | Non Exec Director | 28/11/2013 | 26/11/2021 |
| Jeffrey Sherman | Non Exec Director | 14/10/2019 | 30/04/2021 |
| Richard Sheridan | CFO | 25/02/2013 | 31/07/2019 |
| Carlo Campiciano | CFO | 31/07/2019 | |
| Peter Dykes | Non Exec Director | 30/11/2012 | 14/11/2015 |
| Stephen Brockhurst | Director | 04/05/2015 | 12/11/2015 |
| Shane Hartwig | Non Exec Director | 21/07/2010 | 04/05/2015 |
| Robert Whitton | Non Exec Chairman | 30/11/2012 | 28/11/2013 |
| Romy Soekarno | Independent Director | 23/08/2012 | 28/11/2013 |
| Robert Crossman | Non Exec Director | 23/07/2013 | 25/11/2013 |
| Edward Foo | Independent Director | 30/11/2012 | 11/11/2013 |
| Barry Tudor | CEO, Managing Director | 03/05/2012 | 17/09/2013 |
| Emmanuel Correia | Executive Chairman | 21/07/2010 | 30/11/2012 |
| Jim Malone | Non Exec Director | 15/02/2011 | 30/11/2012 |
Date of first appointment, title may have changed.
Contact Us | Financial Services Guide | Privacy Policy
This website is owned and operated by Investogain Pty Limited.
ABN 88 129 443 447 | AFSL 334036
Information provided is of a general nature and not for trading or advice.
Copyright © 2002-2025 Investogain Pty Limited. All rights reserved.
